Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

Safety warnings about the risk of developing ketoacidosis or urinary tract infection (UTI) have been added to the labels of sodium-glucose cotransporter-2 inhibitors, used for treatment of type 2 diabetes. In the image, close up of a dipstick showing UTI

The US FDA’s safety review of SGLT2 inhibitors found 19 cases of life-threatening blood infections and kidney infections – which began as urinary tract infections (UTIs). In the image, close up of a dipstick showing a UTI

Source  Dr P Marazzi / Science Photo Library